hrp0084p2-530 | Puberty | ESPE2015

Nephrogenic Diabetes Insipidus with Partial Response to Ddavp Caused by a Novel AVPR2 Splice Site Mutation

Schernthaner-Reiter Marie Helene , Adams David , Nilsson Ola , Trivellin Giampaolo , Ramnitz Mary Scott , Raygada Margarita , Golas Gretchen , Faucz Fabio R. , Dileepan Kavitha , Lodish Maya B. , Lee Paul R. , Markello Thomas C. , Tifft Cynthia J. , Gahl William A. , Stratakis Constantine A.

Background: Congenital diabetes insipidus (DI) can be due to mutations in the arginine vasopressin (AVP) gene (familial neurohypophyseal DI), the AVP receptor type 2 (AVPR2) or aquaporin 2 (AQP2) genes (congenital nephrogenic DI, NDI). The clinical manifestation of congenital NDI, especially the response to AVP, can vary greatly depending on the functional effect of the AVPR2 mutation. Here we present two male siblings with NDI and partial response to ddAVP.<p class="abste...

hrp0092fc2.1 | Bone, Growth Plate and Mineral Metabolism Session 1 | ESPE2019

Continued Improvement in Clinical Outcomes with Burosumab, a Fully Human Anti-FGF23 Monoclonal Antibody: Results from a 3-Year, Phase 2, Clinical Trial in Children with X-Linked Hypophosphatemia (XLH)

Linglart Agnès , Carpenter Thomas O. , Högler Wolfgang , Imel Erik A. , Portale Anthony A. , Boot Annemieke , Padidela Raja , Van't Hoff William , Mao Meng , Skrinar Alison , Scott Roberts Mary , San Martin Javier , Whyte Michael P.

In children with XLH, excess FGF23 causes hypophosphatemia with consequent rickets, skeletal deformities, and impaired growth and mobility. We previously reported that burosumab improved phosphate homeostasis and rickets in children with XLH. Here, we report final data from this Phase 2 Study CL201 (NCT02163577).Fifty-two children with XLH (5-12 years old, Tanner ≤ 2) were randomized 1:1 to receive subcutaneous burosumab every 2 (Q2W) or 4 (Q4W) we...

hrp0092fc2.2 | Bone, Growth Plate and Mineral Metabolism Session 1 | ESPE2019

Benefits of Long-Term Burosumab Persist in 11 Girls with X-Linked Hypophosphatemia (XLH) Who Transitioned into Adolescence During the Phase 2 CL201 Trial

Boot Annemieke , Carpenter Thomas O. , Högler Wolfgang , Imel Erik A. , Portale Anthony A. , Linglart Agnès , Padidela Raja , Van't Hoff William , Mao Meng , Skrinar Alison , Scott Roberts Mary , San Martin Javier , Whyte Michael P.

In children with XLH, excess FGF23 causes hypophosphatemia with consequent rickets, skeletal deformities, and impaired growth and mobility. We reported that burosumab improved phosphate homeostasis and rickets in children with XLH. Here, we present data on 11/52 subjects (all girls) who developed fused growth plates during the phase 2 study CL201 (NCT02163577).In CL201, 52 subjects (Baseline: 5-12 years-old, Tanner ≤ 2) were randomized 1:1 to recei...

hrp0092s1.2 | Novel Advances in Diabetes and Obesity | ESPE2019

The Gut Microbiome and Obesity

Scott Frank

The obesity pandemic is likely multifactorial, comprised primarily of reduced caloric expenditure and increased caloric intake secondary to dietary changes, coupled with host genetic predisposition and other environmental exposures. The role of the host microbiome in metabolism, energy expenditure, and metabolic disorders, including obesity, has more recently come under scrutiny as well. For example, several perturbations in the host microbiome have been associated with obesit...

hrp0084s4.1 | Management of thyroid disorders: Current best practice | ESPE2015

Management of Hyperthyroidism in Children

Rivkees Scott

Background: The most prevalent cause of thyrotoxicosis in children is Graves’ disease (GD), and remission occurs only in a modest proportion of patients. The treatment of GD involves the use of antithyroid medications (ATDs), radioactive iodine (RAI; (131I), or surgical thyroidectomy.Objective and hypotheses: This presentation will focus on the risks and benefits of the different treatment options for GD.Method: ATDs are the m...

hrp0082p2-d3-503 | Perinatal and Neonatal Endocrinology | ESPE2014

Survey of Opinion on the Antenatal and Surgical Management of Disorders of Sex Development and Congenital Adrenal Hyperplasia

White Mary , Hewitt Jacqueline

Background: Congenital adrenal hyperplasia (CAH) is characterised by elevated adrenal androgens which can lead to virilisation of affected females.Objective and hypotheses: To outline clinical opinion on two controversial aspects of CAH management (antenatal dexamethasone and genital surgery of affected females) which was hypothesised would differ between regional centres.Methods: A survey was conducted via the Aus...

hrp0084s5.3 | Developmental Programming: Novel concepts | ESPE2015

Intergenerational Programming of Metabolic Disease via the Paternal Lineage

Patti Mary Elisabeth

Background: Common metabolic diseases, including diabetes and obesity, are the result of interactions between genes and environment. It is well-recognized that the maternal intrauterine environment is an important modifier of this risk. Thus, fetuses carried by women who are obese, diabetic or suffer from suboptimal nutrition are at increased risk of insulin resistance, obesity, type 2 diabetes (T2D), and cardiovascular disease as adults. Emerging data indicate that paternal e...

hrp0092rfc13.1 | Adrenals and HP Axis | ESPE2019

Children and Adolescents in the United States with Congenital Adrenal Hyperplasia are not at Increased Risk for Attention-Deficit/Hyperactivity Disorder

Harasymiw Lauren , Grosse Scott , Sarafoglou Kyriakie

Background: Congenital adrenal hyperplasia (CAH) is a rare form of adrenal insufficiency characterized by impaired cortisol synthesis leading to excessive adrenal androgen production. Little is known regarding the effects of early and chronic androgen exposure in children with CAH, and whether this exposure may increase the risk of developing attention-deficit/hyperactivity disorder (ADHD) during childhood. The only study on the subject, based on a small sampl...

hrp0092p1-35 | Diabetes and Insulin | ESPE2019

The Impact of CGM Availability: Real World Data From a Population Based Clinic

Sanderson Elaine , Smith Grant , Abraham Mary , Jones Timothy , Davis Elizabeth

Real-world studies reporting the impact of continuous glucose monitoring (CGM) in children with Type 1 diabetes (T1D) are limited. In April 2017 CGM became fully subsidised in Australia for children with T1D <21yrs. We report the impact of this in a large population based sample of paediatric diabetes (n=1093). Almost all (99%) children (age < 18yr) with diabetes in Western Australia attend a single paediatric diabetes centre.Pri...

hrp0092p2-62 | Diabetes and Insulin | ESPE2019

The Effect of Carbohydrate Recognition and Counting Ability on Glycemic Control in Pediatric Patients with Type 1 Diabetes

Minutti Carla , Mullen Mary , Bindiganavle Aparna , Parish Anthony

Many factors contribute to the glycemic control in pediatric patients with type 1 diabetes mellitus (T1DM). The purpose of this IRB approved study was to determine if there was a significant correlation between the ability of pediatric patients with TiDM to accurately recognize and count carbohydrates and their hemoglobin A1C (HgbA1C). T1DM patients aged 12-17 years completed the Koontz PedCarbQuiz (PCQ) . Demographic and clinical data was extracted from the electronic health ...